How to Factor N_1 and N_2 When p_1=p_2 mod 2^t

Let $N_1=p_1q_1$ and $N_2=p_2q_2$ be two different RSA moduli. Suppose that $p_1=p_2 \bmod 2^t$ for some $t$, and $q_1$ and $q_2$ are $\alpha$ bit primes. Then May and Ritzenhofen showed that $N_1$ and $N_2$ can be factored in quadratic time if $$t \geq 2\alpha+3.$$ In this paper, we improve this lower bound on $t$. Namely we prove that $N_1$ and $N_2$ can be factored in quadratic time if $$t \geq 2\alpha+1.$$ Further our simulation result shows that our bound is tight

How to Factor N1 and N2 When p1 = p2 mod 2 t

Abstract. Let N1 = p1q1 and N2 = p2q2 be two different RSA moduli. Suppose that p1 = p2 mod 2 t for some t, and q1 and q2 are α bit primes. Then May and Ritzenhofen showed that N1 and N2 can be factored in quadratic time if t ≥ 2α + 3. In this paper, we improve this lower bound on t. Namely we prove that N1 and N2 can be factored in quadratic time if t ≥ 2α + 1. Further our simulation result shows that our bound is tight

二値推移モデルとクロスオーバーデザインへの応用

東京理科大学201

Mn(III)-Based Synthesis of 1,2-Dioxolanes, Reaction Mechanism, and Related Reaction

The manganese(III)-based aerobic oxidation of arylacetylenes with 2,4-pentanedione at ambient temperature unexpectedly gave the 1,2-dioxolane derivatives in moderate yields together with a small amount of the oxiranes. The 1,2-dioxolanes underwent silica gel-assisted contraction to quantitatively give the oxiranes. The reaction pathway for the formation of the 1,2-dioxolanes and the by-product was discussed

Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.

To investigate whether single nucleotide polymorphisms (SNP) of drug transporter proteins for TDF is a risk factor for TDF-related renal function decrement.This study investigated the association between 3 SNPs (ABCC2-24, 1249, and ABCB1 2677), which are shown to be associated with TDF-induced tubulopathy, and clinically important renal outcomes (>10ml/min/1.73m2 decrement in eGFR relative to baseline, >25% decrement in eGFR, and eGFR 10ml/min/1.73m2 and those without such decrement (ABCC2: -24, p = 0.53, 1249, p = 0.68; ABCB1: 2677, p = 0.74), nor between those without and with the other two renal outcomes (>25% decrement: ABCC2: -24, p = 0.83, 1249, p = 0.97, ABCB1: 2677, p = 0.40; eGFR <60ml/min/1.73m2: ABCC2: -24, p = 0.51, 1249, p = 0.81, ABCB1: 2677, p = 0.94). Logistic regression analysis showed that the risk genotype of the three SNPs were not associated with any of the three renal outcomes, respectively. Logistic regression model that applied either dominant, recessive, or additive model yielded the same results.SNPs of the drug transporters for TDF are not associated with clinically important renal outcomes in patients who initiated TDF-containing ART

A Novel High-Throughput Screening Method for a Human Multicentric Osteosarcoma-Specific Antibody and Biomarker Using a Phage Display-Derived Monoclonal Antibody

Osteosarcoma is a malignant tumor that produces neoplastic bone or osteoid osteoma. In human multicentric osteosarcoma (HMOS), a unique variant of human osteosarcoma (HOS), multiple bone lesions occur simultaneously or asynchronously before lung metastasis. HMOS is associated with an extremely poor prognosis, and effective treatment options are lacking. Using the proteins in our previously generated HMOS cell lines as antigens, we generated antibodies using a human antibody phage library. We obtained antibody clones recognizing 95 independent antigens and developed a fluorescence probe-based enzyme-linked immunosorbent assay (ELISA) technique capable of evaluating the reactivity of these antibodies by fluorescence intensity, allowing simple, rapid, and high-throughput selection of antibody clones. These results were highly correlated with those using flow cytometry. Subsequently, the HMOS cell lysate was incubated with the antibody, the antigen&ndash;antibody complex was recovered with magnetic beads, and the protein bands from electrophoresis were analyzed using liquid chromatography-mass spectrometry (LC/MS). CAVIN1/polymerase I transcript release factor was specifically detected in the HMOS cells. In conclusion, we found via a novel high-throughput screening method that CAVIN1/PTRF is an HMOS-specific cell membrane biomarker and an antigen capable of producing human antibodies. In the future, antibody&ndash;drug conjugate targeting of these specific proteins may be promising for clinical applications